NJ State Employees Deferred Compensation Plan decreased its stake in shares of Alkermes Plc (NASDAQ:ALKS) by 33.3% during the second quarter, Holdings Channel reports. The fund owned 20,000 shares of the company’s stock after selling 10,000 shares during the period. NJ State Employees Deferred Compensation Plan’s holdings in Alkermes Plc were worth $1,159,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. FMR LLC raised its stake in shares of Alkermes Plc by 0.4% in the first quarter. FMR LLC now owns 22,882,118 shares of the company’s stock valued at $1,338,604,000 after buying an additional 86,546 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Alkermes Plc by 4.3% in the first quarter. Vanguard Group Inc. now owns 12,096,635 shares of the company’s stock valued at $707,654,000 after buying an additional 497,421 shares during the last quarter. BlackRock Inc. raised its stake in shares of Alkermes Plc by 5,927.5% in the first quarter. BlackRock Inc. now owns 10,292,601 shares of the company’s stock valued at $602,115,000 after buying an additional 10,121,839 shares during the last quarter. Primecap Management Co. CA raised its stake in shares of Alkermes Plc by 23.2% in the first quarter. Primecap Management Co. CA now owns 7,856,543 shares of the company’s stock valued at $459,608,000 after buying an additional 1,480,273 shares during the last quarter. Finally, Woodford Investment Management Ltd raised its stake in shares of Alkermes Plc by 0.3% in the first quarter. Woodford Investment Management Ltd now owns 7,470,528 shares of the company’s stock valued at $437,026,000 after buying an additional 19,400 shares during the last quarter. Institutional investors own 97.67% of the company’s stock.

Alkermes Plc (NASDAQ ALKS) opened at 53.77 on Friday. Alkermes Plc has a 1-year low of $41.93 and a 1-year high of $63.40. The firm’s market capitalization is $8.26 billion. The company’s 50-day moving average price is $57.87 and its 200-day moving average price is $57.45.

Alkermes Plc (NASDAQ:ALKS) last posted its quarterly earnings data on Thursday, July 27th. The company reported $0.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.02. The business had revenue of $218.80 million for the quarter, compared to analysts’ expectations of $216.54 million. Alkermes Plc had a negative return on equity of 14.26% and a negative net margin of 19.65%. The business’s revenue was up 12.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.01) EPS. Equities research analysts expect that Alkermes Plc will post ($0.04) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Alkermes Plc (NASDAQ:ALKS) Shares Sold by NJ State Employees Deferred Compensation Plan” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/08/05/alkermes-plc-nasdaqalks-shares-sold-by-nj-state-employees-deferred-compensation-plan.html.

ALKS has been the topic of several research analyst reports. ValuEngine upgraded Alkermes Plc from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Cowen and Company restated a “buy” rating on shares of Alkermes Plc in a research report on Friday, April 28th. J P Morgan Chase & Co set a $78.00 target price on Alkermes Plc and gave the company a “buy” rating in a research report on Saturday, July 1st. BidaskClub lowered Alkermes Plc from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Finally, Credit Suisse Group set a $70.00 target price on Alkermes Plc and gave the company a “buy” rating in a research report on Friday, May 19th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $62.20.

In other news, Director Richard F. Pops sold 50,000 shares of Alkermes Plc stock in a transaction that occurred on Wednesday, May 17th. The shares were sold at an average price of $58.19, for a total transaction of $2,909,500.00. Following the completion of the transaction, the director now directly owns 680,406 shares in the company, valued at $39,592,825.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard F. Pops sold 25,000 shares of Alkermes Plc stock in a transaction that occurred on Wednesday, May 10th. The shares were sold at an average price of $57.29, for a total transaction of $1,432,250.00. Following the transaction, the director now owns 655,406 shares of the company’s stock, valued at $37,548,209.74. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 134,500 shares of company stock worth $7,778,715. Insiders own 5.34% of the company’s stock.

About Alkermes Plc

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes Plc (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes Plc (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes Plc and related companies with MarketBeat.com's FREE daily email newsletter.